Using SOX2 ChIP-seq and microarray analysis, Fang et al. found 4883 binding sites for SOX2 in the GBM cancer genome compared to IgG control ChIP-seq data, and identified 489 genes and 105 precursor microRNAs whose expression was altered in response to SOX2 knockdown in GBM cells [37]. This evidence concerns the gene SOX2 and cancer.